HILDEN and BERLIN, Germany – QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed. Approximately one-third […]
OMAHA, Neb. & THE WOODLANDS, Texas– Transgenomic, Inc. (OTCBB: TBIO) and Power3 Medical Products, Inc. (OTCBB: PWRM) today announced that, following mediation through the offices of the United States District Court for the District of Nebraska, all pre-existing litigations and disputes between the companies have been resolved and terminated, effective immediately. The dispute related to […]
AN DIEGO — Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced highlights of the Company’s 2011 performance and accomplishments, as well as preliminary activities and goals for the first part of 2012. Initial 2011 Performance Results Total revenue growth of approximately 23 percent year-over-year for 2011 (unaudited). Over […]
OMAHA, Neb. – Transgenomic, Inc. (OTC/BB: TBIO) today announced that it has entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) in the aggregate amount of $3.0 million with entities (the “Investors”) associated with Third Security, LLC, a leading life sciences investment firm. “We are very pleased with the additional investment by Third […]
IRVINE, Calif. and AMSTERDAM — Agendia, an innovative molecular cancer diagnostics company, today announced that the company has signed a contract with Blue Shield of California, making Agendia an in-network provider. The move paves the way for future in-network coverage for MammaPrint® and other Agendia tests by Blue Cross affiliates across the United States. Developed […]
SEATTLE — Adaptive TCR Corporation, a leading provider of next generation sequencing assays for the adaptive immune system marketed under the brand name immunoSEQ, announced today it has changed its name to Adaptive Biotechnologies Corporation effective immediately. The name change reflects the expanded capabilities of the company’s original immune profiling business as well as the […]
CAMBRIDGE, Mass. — Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, has reported a method for detecting individual proteins within microfabricated polymer arrays produced by Sony DADC. Quanterix recently entered into a collaboration with Sony DADC for the development and manufacture of […]
ALAMEDA, Calif.–BioTime, Inc. (NYSE Amex: BTX) today announced agreements with USCN Life Science, Inc. (USCN) of Wuhan, China, granting BioTime an option to license USCN’s antibody-producing cell lines and certain related technology that may be used by BioTime and its subsidiary OncoCyte Corporation for the large-scale manufacture of the antibody components of PanC-DxTM. PanC-DxTM is […]
ALAMEDA, Calif.–BioTime, Inc., and BioTime’s subsidiary OncoCyte Corporation today announced plans for the development of PanC-DxTM, a novel diagnostic device discovered at BioTime and OncoCyte to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check-ups. PanC-DxTM would require only a simple antibody-based blood […]
SUNNYVALE, Calif.–Arrayit Corporation has approved the spin-off of its majority owned subsidiary, Arrayit Diagnostics, Inc. Arrayit Corporation will distribute to its existing shareholders its 78.18% interest in Arrayit Diagnostics as a stock dividend. The stock dividend distribution date and further details are expected to be announced early in the first quarter of 2012. Since July […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
